Aurora A kinase inhibition compromises its antitumor efficacy by elevating PD-L1 expression
Aurora A plays a critical role in G2/M transition and mitosis, making it an attractive target for cancer treatment. Aurora A inhibitors showed remarkable antitumor effects in preclinical studies, but unsatisfactory outcomes in clinical trials have greatly limited their development. In this study, th...
Main Authors: | Xiaobo Wang, Jing Huang, Fenglin Liu, Qian Yu, Ruina Wang, Jiaqi Wang, Zewen Zhu, Juan Yu, Jun Hou, Joong Sup Shim, Wei Jiang, Zengxia Li, Yuanyuan Zhang, Yongjun Dang |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Clinical Investigation
2023-05-01
|
Series: | The Journal of Clinical Investigation |
Subjects: | |
Online Access: | https://doi.org/10.1172/JCI161929 |
Similar Items
-
Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth
by: Galina Gritsina, et al.
Published: (2023-08-01) -
Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
by: Thuy T. Tran, et al.
Published: (2023-04-01) -
L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression
by: Yuanyuan Zhang, et al.
Published: (2022-06-01) -
Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer
by: Alessio Stefani, et al.
Published: (2022-10-01) -
Decitabine priming increases anti–PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models
by: Xiang Li, et al.
Published: (2023-04-01)